Last reviewed · How we verify
NCT03283800: CIVIL
Copper Impact on Venous Insufficiency and Lipodermatosclerosis
NA trial testing Copper impregnated compression stocking in Lipodermatosclerosis in 16 participants. Completed in 9 January 2017.
9 January 2017
Quick facts
| Lead sponsor | Croydon Health Services NHS Trust |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 16 |
| Start date | 23 September 2015 |
| Primary completion | 9 January 2017 |
| Estimated completion | 9 January 2017 |
Drugs / interventions tested
- Copper impregnated compression stocking
- Normal compression stocking
Conditions studied
- Lipodermatosclerosis — all drugs for Lipodermatosclerosis →
- Chronic Venous Insufficiency — all drugs for Chronic Venous Insufficiency →
- Venous Insufficiency — all drugs for Venous Insufficiency →
- Varicose Veins — all drugs for Varicose Veins →
Sponsor
Croydon Health Services NHS Trust
Who can join
Eligibility, any sex, with Lipodermatosclerosis or Chronic Venous Insufficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Venous disease has an adverse impact on the quality of life of patients and the NHS spends considerable resources on this chronic condition. Copper has been shown to promote new blood vessel formation and therefore improve blood supply to the affected area and possibly skin conditions. Copper has also been shown to have strong antimicrobial properties. We plan to perform a study whereby patients who would normally be given leg stockings will be asked to wear similar stockings except that one of the stockings will contain copper fibers. Neither the patient nor the clinician will know which is which. Photographs of the leg conditions will be taken at baseline, 2, 4 and 8 weeks to evaluate healing. Benefit will be evaluated by a symptom questionnaire, severity scoring tools and healing scores taken from the serial photographs.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Role of Copper Homeostasis in Brain Disease.
An Y, Li S, Huang X, Chen X, et al · · 2022 · cited 108× · PMID 36430330 · DOI 10.3390/ijms232213850 -
Upcoming treatments for morphea.
Wenzel D, Haddadi NS, Afshari K, Richmond JM, et al · · 2021 · cited 20× · PMID 34272836 · DOI 10.1002/iid3.475 -
Impact of copper compression stockings on venous insufficiency and lipodermatosclerosis: A randomised controlled trial.
Arendsen LP, Vig S, Thakar R, Sultan AH. · · 2019 · cited 9× · PMID 30149775 · DOI 10.1177/0268355518795329
Verify or expand the search:
- PubMed search for NCT03283800
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Croydon Health Services NHS Trust trials
Trials by the same sponsor.
- NCT04480684 — The Effect of Perineal Wound Infection on the Anal Sphincter · completed
- NCT03284749 — Effect of Copper on the Healing of Obstetric Wounds · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03283800 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Croydon Health Services NHS Trust
- Last refreshed: 15 September 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03283800.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing